Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183072 | 0.83 | NR1H2 (0.47) | PDK2ATM | |
| SCHEMBL21423632 | 0.80 | P2RX7 (0.51) | PDK2P2RX7MEN1KMT2AATM | |
| SCHEMBL599712 | 0.78 | P2RX7 (0.53) | PDK2P2RX7MEN1KMT2AATM | |
| SCHEMBL21423961 | 0.78 | TGFBR1 (0.40) | PDK2P2RX7MEN1KMT2AATM | |
| SCHEMBL24656040 | 0.78 | P2RX7 (0.39) | PDK2P2RX7MEN1KMT2AATM | |
| SCHEMBL17579750 | 0.77 | PDK2 (0.41) | PDK2P2RX7MEN1KMT2AATM | |
| SCHEMBL12233612 | 0.77 | PDK2 (0.52) | PDK2P2RX7HDAC4HDAC1HDAC6 | |
| SCHEMBL10233673 | 0.76 | CPB2 (0.43) | PDK2P2RX7MEN1KMT2AATM | |
| SCHEMBL21423969 | 0.75 | PDK2 (0.39) | PDK2P2RX7MEN1KMT2AATM | |
| SCHEMBL18711410 | 0.75 | CREBBP (0.39) | PDK2P2RX7TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PDK2 465/4885P2RX7 4296/4885MEN1 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.